{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001914","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2021-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.951302+00:00","generated_at":"2026-06-29T00:46:52.785157+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Terns appoints former AstraZeneca CMO Ann Taylor to board","bullets":["Ann E. Taylor, M.D. appointed as Class I director effective Sept 28, 2021.","Dr. Taylor brings >35 years of drug development experience, including CMO of AstraZeneca.","She will receive an initial option grant of 44,000 shares and $40k annual cash retainer.","Her expertise in NASH and clinical development supports Terns' pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001914","json":"https://secwatch.observer/filing/0000950170-21-001914.json","markdown":"https://secwatch.observer/filing/0000950170-21-001914.md","text":"https://secwatch.observer/filing/0000950170-21-001914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017021001914/0000950170-21-001914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017021001914/tern-20210928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:46:52.785157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"026a6c9a2c","claim":"Ann E. Taylor was appointed as Director at Terns Pharmaceuticals, Inc..","evidence_excerpt":"On September 28, 2021, the Board of Directors (the “Board”) of Terns Pharmaceuticals, Inc. (the “Company”) appointed Ann E. Taylor, M.D. to serve as a Class I director until her successor is duly elected and qualified or until her earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017021001914/0000950170-21-001914-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}